Table 2.
APOE allele distribution among the study population and stages of fibrosis in chronic hepatitis C patients, n (%)
|
HCV-patients |
Fibrosis stage in CHC patients4 |
|||||
| Chronic (n = 206) | Clearance (n = 93) | P value | F1-F2 (n = 49) | F3-F4 (n = 38) | P value | |
| Genotypes | ||||||
| ε2ε2 | 2 (1.0) | 0 | - | 0 | 0 | - |
| ε2ε3 | 15 (7.4) | 8 (8.6) | 0.691 | 5 (10.5) | 2 (5.3) | 0.400 |
| ε2ε4 | 2 (1.0) | 0 | - | 0 | 0 | - |
| ε3ε3 | 160 (77.5) | 64 (68.8) | 0.102 | 29 (59.2) | 34 (89.5) | 0.001 |
| ε3ε4 | 26 (12.7) | 19 (20.4) | 0.080 | 14 (28.6) | 1 (2.6) | 0.001 |
| ε4ε4 | 1 (0.5) | 2 (2.2) | 0.181 | 1 (2) | 1 (2.6) | 0.969 |
| Alleles | ||||||
| ε2 | 21 (5.1) | 8 (4.3) | 0.674 | 4 (5.1) | 2 (2.6) | 0.603 |
| ε3 | 361 (87.6) | 155 (83.3) | 0.158 | 78 (78.6) | 70 (93.4) | 0.0222 |
| ε4 | 30 (7.3) | 23 (12.4) | 0.0421 | 16 (16.3) | 4 (4) | 0.0233 |
| HWE | 0.438 | 0.892 | - | 0.910 | 0.286 | - |
1
ε4 allele was associated with SC OR = 0.55, 95%CI: 0.31-0.98, P = 0.042.
2
ε3 allele was associated with severe fibrosis (F3-F4) OR = 2.99, 95%CI: 1.13-7.87, P = 0.021.
3
ε4 allele was associated with mild fibrosis (F1-F2) OR = 0.091, 95%CI: 0.01-0.75, P = 0.020.
4
Liver damage was assessed in 87 chronic hepatitis C patients. CHC: Chronic hepatitis C; HWE: Hardy-Weinberg Equilibrium.